What Is Follistatin 344?
Follistatin 344 (FST344) is the longer precursor isoform of human follistatin, encoded by the FST gene through alternative splicing. It contains 344 amino acids, compared with 317 amino acids in the shorter FST317 isoform. The two isoforms share the same core follistatin domains but have different C-terminal regions.
Follistatin is a single-chain, cysteine-rich glycoprotein with three homologous follistatin domains. The human FST gene and its FST344 transcript were characterized through molecular cloning, sequencing and structural studies.
Research Overview Table
Chemical and Molecular Characteristics
Follistatin 344 is a 344-amino-acid precursor protein with a cysteine-rich structure. Structural characterization identified 36 cysteine residues in the mature coding sequence and three homologous follistatin domains. The FST344 precursor also contains a C-terminal region that differs from the shorter FST317 isoform.
Follistatin is a glycoprotein with cysteine-rich domains containing disulfide linkages. A basic region within the first follistatin domain is associated with heparin binding, while the C-terminal region contributes additional structural characteristics that distinguish FST344 from FST317.
Certificates:
Mechanism of Action Under Investigation
Follistatin 344 is investigated as an extracellular binding protein that interacts with TGF-β superfamily ligands, including activin and myostatin. FST344 can bind these ligands and interfere with their interaction with type II receptors. Studies of follistatin isoforms have shown that ligand binding and cell-surface association vary between isoforms, indicating that the C-terminal structure of FST344 can influence its molecular behavior.
FST344-specific research has used AAV1-FST344 gene delivery to investigate the biological consequences of increasing FST344 expression in experimental systems. These studies provide evidence for FST344-associated changes in signaling and tissue responses, but they do not establish that every molecular interaction identified in studies of other follistatin isoforms occurs identically with FST344.
The mechanism is therefore best understood as ligand sequestration and interference with ligand–receptor interaction, rather than direct activation or inhibition of a cell-surface receptor by FST344 itself. Experimental approaches used to investigate follistatin–ligand interactions include ligand-binding assays, competitive binding studies, recombinant protein analysis, cell-based assays, and structural studies.
Scientific Research Context
Follistatin 344 appears in the scientific literature because researchers have studied it as an experimental form of follistatin. Research has included in vitro studies and preclinical animal models, which make up most of the current evidence. A limited amount of research has also moved into early human studies. Overall, the evidence remains predominantly preclinical, with human research making up only a small part of the available literature.
Follistatin 344 Biology and Biological Pathways
Primary Biological Function
Follistatin is a regulatory glycoprotein that controls signaling by members of the TGF-β superfamily. Its primary biological function is to bind activin, myostatin, and related ligands and regulate their biological activity. This role makes the follistatin system relevant to the study of processes controlled by TGF-β superfamily signaling.
Relevant Metabolic or Signaling Pathways
Follistatin-related research connects skeletal-muscle protein metabolism with TGF-β superfamily signaling. The signaling pathways include activin and myostatin pathways, which primarily activate SMAD2/3, and BMP pathways, which primarily activate SMAD1/5/8. These pathways interact with processes that regulate muscle protein synthesis and breakdown, making both metabolic and signaling pathways relevant to follistatin research.
Tissue-Specific Biology
Follistatin expression has been reported in the pituitary, ovary, testis, skeletal muscle, liver, placenta, kidney, brain, adrenal tissue, thyroid and bone marrow. FST344-specific mRNA studies in rats also found tissue-specific expression in the kidney, muscle, brain cortex, heart, and thymus during postnatal development.
Experimental Biomarkers
Researchers measure FST gene expression and follistatin protein levels to characterize this biological system. Depending on the research question, studies may also measure activin, myostatin, BMPs, and downstream SMAD proteins. These markers help researchers characterize changes within the relevant signaling network without relying on a single biological measurement.
Laboratory Investigation Methods
Researchers use quantitative RT-PCR, Western blotting, and immunohistochemistry to examine FST344 expression and follistatin protein in experimental samples.
Experimental Models Used in Published Research
Published FST344 research includes cultured human cells, mouse models, and cynomolgus macaques. These models range from controlled cellular systems to whole-animal models. Their limitations mainly relate to the biological complexity of cell systems and the species differences that affect how findings translate between experimental animals and humans.
Cell-Based Models
MCF-7 human breast cancer cells have been used with an FST344 expression plasmid. This cell model provides a controlled human cellular setting, but it cannot reproduce interactions among tissues, organs, and whole-body physiology.
Mouse Models
Published FST344 research has used normal, dystrophic and genetically modified mice, including Ldlr−/− mice in an AAV1-FST344 study. Mouse models provide an intact mammalian system for FST344 research, but species-specific differences limit how directly findings can be applied to human biology.
Cynomolgus Macaque Models
Cynomolgus macaques (Macaca fascicularis) have been used in AAV1-FST344 studies. Nonhuman primates provide greater biological similarity to humans than rodents, but they remain a different species, and published studies have involved relatively small numbers of animals.
Limitations of Current Research
Evidence Is Predominantly Preclinical
Most FST344 research remains preclinical, with evidence coming mainly from animal studies and laboratory models. Human studies have been limited to early clinical investigations of AAV1-FST344 gene transfer, including a six-participant Phase 1/2a study. The limited size and scope of the human evidence restrict conclusions about FST344 in humans.
Human Clinical Evidence
Human evidence for Follistatin-344 remains limited because the available clinical studies have small participant groups and early-stage designs. These factors make it difficult to draw broader conclusions from the current clinical evidence.
Species Differences
Animal findings do not always translate directly to humans. The FST344 literature notes that results from one species may not apply to another. Differences in physiology and biological responses can therefore make it difficult to know how closely preclinical findings reflect what would occur in humans.
Study Design Limitations
The available human studies used small, open-label, and non-randomized designs. The sIBM study also included an exercise program alongside FST344 gene transfer, making it difficult to separate the effects of the gene-transfer intervention from those of exercise.
Independent Replication
The FST344 clinical literature remains limited, with relatively few human studies available for comparison. This makes independent replication important for determining whether observations remain consistent across different populations, research groups, and study designs. The current literature does not provide a sufficiently broad clinical evidence base to draw strong conclusions about reproducibility.
Long-Term Evidence
Long-term human evidence for FST344 remains limited. Although preclinical research has followed FST344 expression for extended periods, the available human studies do not provide comparable long-term data. This leaves uncertainty about how FST344-related effects may develop or persist over longer periods in humans.
Analytical Documentation
HPLC can provide chromatographic information about a protein sample and has been used in published follistatin purification and characterization studies. LC-MS can provide molecular-mass and sequence-related information and has also been used for follistatin analysis.
NMR can provide structural information when suitable for the material, but it is not a primary method reported for Follistatin 344 in the literature reviewed.
A Certificate of Analysis (COA) records batch-specific test methods, results, and specifications. Reviewing these records helps confirm that the material meets its stated analytical requirements. Analytical documentation verifies product identity and quality, not biological performance.
Storage and Laboratory Handling
Store Follistatin 344 according to the product specifications. The supplied Certificate of Analysis (COA) lists 2–8°C as the storage condition for the lyophilized material. Keep the vial sealed and protected from conditions that could affect the material during storage.
Qualified laboratory personnel should handle the material using clean laboratory practices to reduce the risk of contamination. Keep the vial closed when not in use and use appropriate laboratory equipment and work areas. Follow the product documentation and applicable laboratory procedures for storage and handling. Follistatin 344 is intended for laboratory research use only.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.